김지원

  #소화기암#두경부암#기타 고형암의 항암화학요법

학력

2005 서울대학교 의학과 졸업
2014 서울대학교 의학과 분자종양의학 석사
2016 서울대학교 임상의과학과 박사과정 수료

경력

2005.3 ~ 2006.2 서울대학교병원 수련의
2006.3 ~ 2010.2 서울대학교병원 내과 전공의
2010.3 ~ 2013.4 공중보건의사
2013.5 ~ 2015.2 서울대학교병원 혈액종양내과 전임의
2015.3 ~ 현재 분당서울대학교병원 혈액종양내과 조교수

논문

Xu W, Kim JW (공동1저자), Jung WJ, Koh Y, Yoon SS. Crizotinib in combination with everolimus synergistically inhibits proliferation of ALK-positive anaplastic large cell lymphoma. Cancer Res Treat. 2017 Jun 19. doi: 10.4143/crt.2016.357. [Epub ahead of print]

Kim JW (공동1저자), Lee HS, Nam KH, Ahn S, Kim JW, Ahn SH, Park DJ, Kim HH, Lee KW. PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer. Oncotarget. 2017 Jun 28;8(53):90948-90958.

Kim JW (공동1저자), Lee KW, Kim KP, Lee JH, Hong YS, Kim JE, Kim SY, Park SR, Nam BH, Cho SH, Chung IJ, Park YS, Oh HS, Lee MA, Kang HJ, Park YL, Song EK, Han HS, Lee KT, Shin DB, Kang JH, Zang DY, Kim JH, Kim TW. Efficacy and safety of FOLFIRI regimen in elderly versus non-elderly patients with metastatic colorectal or gastric cancer. Oncologist. 2017 Mar;22(3):293-303.

Kim JW (제1저자), Kim MG, Lee HJ, Koh Y, Kwon JH, Kim I, Park S, Kim BK, Oh JM, Kim KI, Yoon SS. Topical Recombinant Human Epidermal Growth Factor for Oral Mucositis Induced by Intensive Chemotherapy with Hematopoietic Stem Cell Transplantation: Final Analysis of a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial. PLoS One. 2017 Jan 3;12(1):e0168854.

Nam AR, Kim JW (공동1저자), Cha Y, Ha H, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ. Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget. 2016 Sep 6;7(36):58007-58021.

Nam AR, Kim JW (공동1저자), Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ. Src as a therapeutic target in biliary tract cancer. Mol Cancer Ther. 2016 Jul;15(7):1515-24.

Kim JW (제1저자), Kim DK, Min A, Lee KH, Nam HJ, Kim JH, Kim JS, Kim TY, Im SA, Park IA. Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer. J Cancer Res Clin Oncol. 2016 Jan;142(1):157-65.

Kim JW (제1저자), Min CK, Mun YC, Park Y, Kim BS, Nam SH, Koh Y, Kwon JH, Choe PG, Park WB, Kim I. Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy. J Clin Virol. 2015 Dec;73:64-9.

Kim JW (공동1저자), Kim SW, Tada K, Fukuda T, Lee JH, Lee JJ, Kwon JH, Bang SM, Kim I, Yoon SS, Lee JS, Park S. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study. Ann Hematol. 2014 Aug;93(8):1345-51.

Kim JW (공동1저자), Koh Y, Kim DW, Ahn YO, Kim TM, Han SW, Oh DY, Lee SH, Im SA, Kim TY, Heo DS, Bang YJ. Clinical implications of VEGF, TGF-β1, and IL-1β in patients with advanced non-small cell lung cancer. Cancer Res Treat. 2013 Dec;45(4):325-33.

Kim JW (제1저자), Kim JH, Im SA, Lee KH, Kim JS, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy. Cancer Chemother Pharmacol. 2013 Nov;72(5):1023-9.

Kim JW (제1저자), Kim JH, Im, SA, Kim YJ, Han HS, Kim JS, Lee KH, Kim TY, Han SW, Jeon YK, Oh DY, Kim TY, Park IA.HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2013 Jul;72(1):109-15.

Bae JY, Kim JW (공동1저자), Kim I. Low-dose 1,25-dihydroxyvitamin D3 combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis. Oncol Rep. 2013 Jul;30(1):485-91.

Kim KI, Kim JW (공동1저자), Lee HJ, Kim BS, Bang SM, Kim I, Oh JM, Yoon SS, Lee JS, Park S, Kim BK. Recombinant human epidermal growth factor on oral mucositis induced by intensive chemotherapy with stem cell transplantation. Am J Hematol. 2013 Feb;88(2):107-12.

Kim JW (제1저자), Kim JH, Im SA, Kim YJ, Han HS, Kim JS, Han SW, Jeon YK, Oh DY, Han W, Kim TY, Park IA, Noh DY, Bang YJ. ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. Oncology. 2012;83(4):218-27.

Kim JW (제1저자), Lee HJ, Yi HG, Kim BS, Bang SM, Kim JS, Kim I, Yoon SS, Lee JS, Kim CS, Park S, Kim BK. Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma. Am J Hematol 2012 May;87(5):479-83.

Kim JW (제1저자), Kim BS, Bang SM, Kim I, Kim DH, Kim WS, Yang DH, Lee JJ, Lee JH, Kim JS, Sohn SK, Yhim HY, Kwak JY, Yoon SS, Lee JS, Park S, Kim BK; Korean Society of Blood and Marrow Transplantation. Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. Ann Hematol. 2011 Dec;90(12):1409-18.

Kim JW (제1저자), Lee JO, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. Am J Clin Oncol. 2011 Apr;34(2):125-9.

Kim JW (제1저자), Kim I, Oh KH, Yoon SS, Oh MD, Song YW, Heo DS, Bang YJ, Han KS, Han JS, Park S, Kim BK. Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the 10-year experience of a single center. Hematology. 2011 Mar;16(2):73-9.

Suh KJ, Sung JH, Kim JW, Han SH, Lee HS, Min A, Kang MH, Kim JE, Kim JW, Kim SH, Lee JO, Kim YJ, Lee KW, Kim JH, Bang SM, Im SA, Lee JS. EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. Oncotarget. 2017 Jul 12;8(38):63901-63910.

Park S, Kim JW, Kim H, Kim JW, Kim YJ, Lee KW, Kim JH, Kim JH, Hwang JH, Choi YR, Cho JY, Yoon YS, Han HS. Prognostic value of p21-activated kinase 4 in resected pancreatic cancer. APMIS. 2017 Aug;125(8):699-707.

Lee JY, Lee JH, Lee H, Kang B, Kim JW, Kim SH, Lee JO, Kim JW, Kim YJ, Lee KW, Kim JH, Choi HS, Lee JS, Bang SM. Epidemiology and management of primary immune thrombocytopenia: A nationwide population-based study in Korea. Thromb Res. 2017 Jul;155:86-91.

Yoo SH, Kim HJ, Kim JH, Lee GW, Lee JH, Kim SH, Kim JW, Kim JW, Lee JO, Kim YJ, Lee KW, Kim JH, Bang SM, Lee JS. Nephrotic syndrome associated with metastatic thymoma treated with chemotherapy. Medicine (Baltimore). 2017 Jan;96(1):e5408.

Choi Y, Kim JW, Nam KH, Han SH, Kim JW, Ahn SH, Park DJ, Lee KW, Lee HS, Kim HH. Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. Gastric Cancer. 2017 Jul;20(4):602-611.

Choi Y, Kim JH, Kim JW, Kim JW, Lee KW, Oh HK, Kim DW, Kang SB, Song C, Kim JS. Preoperative chemoradiotherapy for elderly patients with locally advanced rectal cancer-a real-world outcome study. Jpn J Clin Oncol. 2016 Dec;46(12):1108-1117.

Byun JM, Lee JO, Kang B, Kim JW, Kim SH, Kim JW, Kim YJ, Lee KW, Bang SM, Lee JS. Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population. Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):503-510.e3.

Lee KW, Lee JH, Kim JW, Kim JW, Ahn S, Kim JH. Population-based outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer. J Cancer Res Clin Oncol. 2016 Mar;142(3):687-97.

저서

저서 내용이 없습니다.

보도자료

보도자료 내용이 없습니다.

포스팅

포스팅 내용이 없습니다.

발표자료

발표자료 내용이 없습니다.